You are here

Illumina to pay US$7.1b for cancer test developer Grail

[BENGALURU] Gene sequencing company Illumina Inc will pay US$7.1 billion in cash and stock to buy cancer test startup Grail, the Wall Street Journal reported on Monday, citing people familiar with the matter.

Grail, which is developing a blood test to identify early-stage cancers, was founded by Illumina as a separate company in 2016 and is backed by Amazon.com founder Jeff Bezos and billionaire philanthropist Bill Gates.

The deal for Grail, in which Illumina is the biggest shareholder with a 14.6 per cent stake, is expected to be announced later, according to the report.

The company earlier this month filed for a US initial public offering, without disclosing the offering size.

Grail owners excluding Illumina will get US$3.1 billion in cash and shares in the gene-sequencer maker worth the remaining US$4 billion, the report said.

Your feedback is important to us

Tell us what you think. Email us at btuserfeedback@sph.com.sg

Both Illumina and Grail did not immediately respond to Reuters' requests for comment.

Bloomberg News reported last week Illumina was nearing a deal for Grail.

REUTERS

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes